RespireRx Pharmaceuticals Inc (RSPI)

[LTListener]

Yep.

And for sure there is risk that their candidate drug programs fail at some point in preclinicals; but they genuinely seem enthusiastic and confident given other preclinical efforts and experiences. Considering new VP gets paid at .0015 restricted, recent institutional investor absorbed debt, pushed out to early 2025 and reduced rate to 0%, plus other stakeholders lining up with preferred shares requiring a major payment event to see any ROI at all and then the CEO comments about hoping to open "purse strings" while completing tier 3 NIH preclinicals, hints at where this could be going.

I agree in that when any BP deal is struck, this will be driven by huge money outside IHUB realm, and will be an immediate rocket ship. Given how undervalued the base price is situated, this has that potential to be one stories are told about.